Epigenetic dysregulation in Epstein-Barr virus-associated gastric carcinoma: Disease and treatments

Table 5 Selection of epigenetic therapeutics in cancer chemotherapy

Target	Drug name	Status	Ref.
DNA methylation	Azacitine (5-Aza-CR)	Approved	[72]
	Decitabine (5-Aza-CdR)	Approved	[72]
	Hydralazine	Phase II/III	[73]
	Epigallocatechin-3-gallate (EGCG)	Phase II	[74-76]
	5-Fluoro-deoxycytidine (FdCyd/FDAC)	Phase I/II	[77]
	5-fluoro-2′-deoxycytidine (FCdR)	Phase I/II	[78]
	Procainamide	Phase I	[79]
	Procaine	Phase I	[80]
	Psammaplin A	Phase 0	[81,82]
	RG108	Phase 0	[83-86]
	Zebularine	Phase 0	[87-89]
Histone deacetylases	Vorinostat	Approved	[90]
	Romidepsin	Approved	[90]
	Panobinostat	Phase II	[91]
	SEN196	Phase II	[92]
	Phenyl butyrate	Phase I/II	[93-95]
	Valporic acid	Phase I	[93-95]
	Compound 6J (R = -C4H8)	Phase 0	[96]